Literature DB >> 10762069

Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia.

M J Martínez-Lorenzo1, A Anel, I Monleón, J J Sierra, A Piñeiro, J Naval, M A Alava.   

Abstract

A prominent tyrosine phosphorylated protein of 85 kDa (p85) was detected in highly proliferative sublines derived from the Jurkat T cell leukemia. We undertook a study to characterize the identity of this protein and its possible role in the hyperproliferative phenotypes observed. Using immunoblot and immunoprecipitation techniques, this protein was characterized as the p85 regulatory subunit of phosphatidylinositol 3-kinase. Cell proliferation and p85 tyrosine phosphorylation was not affected by tyrphostin AG-490, an inhibitor of Jak kinases, wortmannin or LY294002, inhibitors of the activity of the catalytic phosphatidylinositol 3-kinase subunit. Herbimycin-A and PPI, inhibitors of src-like protein tyrosine kinases, and genistein, a general tyrosine kinase inhibitor, inhibited p85 tyrosine phosphorylation and induced cell death in the sublines. PD98059, an inhibitor of Mek, inhibited cell growth of the sublines, but not that of the parental cells. It was concluded that tyrosine phosphorylation of p85 is associated with highly proliferative tumoral phenotypes, at least in T cell leukemias, independent of the phosphatidylinositol 3-kinase activity of the catalytic subunit.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762069     DOI: 10.1016/s1357-2725(99)00142-9

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  6 in total

1.  Proline-rich tyrosine kinase 2 controls PI3-kinase activation downstream of the T cell antigen receptor in human T cells.

Authors:  Nicole M Chapman; Ashley N Yoder; Kathryn M Barbón; Mahmood Y Bilal; Sean F Connolly; Jon C D Houtman
Journal:  J Leukoc Biol       Date:  2014-11-11       Impact factor: 4.962

Review 2.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

3.  Targeting HER2 in breast cancer: overview of long-term experience.

Authors:  Evan Lantz; Ivan Cunningham; Gerald M Higa
Journal:  Int J Womens Health       Date:  2010-08-09

4.  Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation.

Authors:  C F de la Cruz-Herrera; M Baz-Martínez; V Lang; A El Motiam; J Barbazán; R Couceiro; M Abal; A Vidal; M Esteban; C Muñoz-Fontela; A Nieto; M S Rodríguez; M Collado; C Rivas
Journal:  Oncogene       Date:  2015-09-28       Impact factor: 9.867

5.  PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells.

Authors:  Soo-Jin Jeong; Arindam Dasgupta; Kyung-Jin Jung; Jee-Hyun Um; Aileen Burke; Hyeon Ung Park; John N Brady
Journal:  Virology       Date:  2007-10-10       Impact factor: 3.616

6.  Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 Silencing

Authors:  Moureq R Alotaibi; Zeinab K Hassan; Salim S Al-Rejaie; Musaad A Alshammari; Mashal M Almutairi; Ali R Alhoshani; Wael A Alanazi; Mohamed M Hafez; Othman A Al-Shabanah
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.